ASX:ALC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Alcidion Group Limited engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom.


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Alcidion Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALC has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

7.4%

ALC

0.4%

AU Healthcare Services

1.9%

AU Market


1 Year Return

-14.7%

ALC

-14.4%

AU Healthcare Services

-8.3%

AU Market

Return vs Industry: ALC matched the Australian Healthcare Services industry which returned -14.4% over the past year.

Return vs Market: ALC underperformed the Australian Market which returned -8.3% over the past year.


Shareholder returns

ALCIndustryMarket
7 Day7.4%0.4%1.9%
30 Day-3.3%-5.9%2.5%
90 Day-3.3%-6.0%13.2%
1 Year-14.7%-14.7%-14.1%-14.4%-4.5%-8.3%
3 Year184.3%184.3%119.9%111.4%19.7%3.9%
5 Yearn/a169.9%147.1%39.8%9.6%

Price Volatility Vs. Market

How volatile is Alcidion Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Alcidion Group undervalued compared to its fair value and its price relative to the market?

4.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ALC (A$0.15) is trading above our estimate of fair value (A$0.01)

Significantly Below Fair Value: ALC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ALC is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.

PE vs Market: ALC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALC is good value based on its PB Ratio (4.6x) compared to the AU Healthcare Services industry average (4.8x).


Next Steps

Future Growth

How is Alcidion Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alcidion Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Alcidion Group performed over the past 5 years?

17.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALC is currently unprofitable.

Growing Profit Margin: ALC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALC is unprofitable, but has reduced losses over the past 5 years at a rate of 17.8% per year.

Accelerating Growth: Unable to compare ALC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (1.4%).


Return on Equity

High ROE: ALC has a negative Return on Equity (-4.12%), as it is currently unprofitable.


Next Steps

Financial Health

How is Alcidion Group's financial position?


Financial Position Analysis

Short Term Liabilities: ALC's short term assets (A$19.6M) exceed its short term liabilities (A$6.7M).

Long Term Liabilities: ALC's short term assets (A$19.6M) exceed its long term liabilities (A$359.6K).


Debt to Equity History and Analysis

Debt Level: ALC is debt free.

Reducing Debt: ALC had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ALC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ALC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.3% per year.


Next Steps

Dividend

What is Alcidion Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Kate Quirke

2.08yrs

Tenure

AU$430,249

Compensation

Ms. Kate Quirke has been Chief Executive Officer and Executive Director of Alcidion Group Ltd. since July 3, 2018 and has been its Managing Director since January 25, 2019. Ms. Quirke served as Chief Execu ...


CEO Compensation Analysis

Compensation vs Market: Kate's total compensation ($USD308.73K) is about average for companies of similar size in the Australian market ($USD270.56K).

Compensation vs Earnings: Insufficient data to compare Kate's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Kate Quirke
MD, CEO & Executive Director2.08yrsAU$430.25k4.15%
A$ 6.2m
Raymond Blight
Co-Founder & Non-Executive Director4.5yrsAU$397.35k10.15%
A$ 15.1m
Colin MacKinnon
CFO & COO1.42yrsAU$1.10m5.96%
A$ 8.9m
Malcolm Pradhan
Chief Medical Officer4.5yrsAU$298.13k13.58%
A$ 20.2m
Tracey Harvey
Human Resources Managerno datano datano data
Melanie Leydin
Joint Company Secretary1.42yrsno datano data
Michael Sapountzis
Joint Company Secretary1.42yrsno datano data

1.4yrs

Average Tenure

Experienced Management: ALC's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Kate Quirke
MD, CEO & Executive Director2.08yrsAU$430.25k4.15%
A$ 6.2m
Raymond Blight
Co-Founder & Non-Executive Director4.5yrsAU$397.35k10.15%
A$ 15.1m
Malcolm Pradhan
Chief Medical Officer4.5yrsAU$298.13k13.58%
A$ 20.2m
Simon Chamberlain
Non-Executive Director1.08yrsno datano data
Nicholas Dignam
Non Executive Director4.5yrsno datano data
Rebecca Wilson
Independent Chair1yrAU$58.33k0.15%
A$ 222.0k

3.3yrs

Average Tenure

Experienced Board: ALC's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.2%.


Top Shareholders

Company Information

Alcidion Group Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Alcidion Group Limited
  • Ticker: ALC
  • Exchange: ASX
  • Founded: 2000
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$148.604m
  • Shares outstanding: 990.69m
  • Website: https://alcidion.com

Location

  • Alcidion Group Limited
  • 9 Yarra Street
  • Level 10
  • South Yarra
  • Victoria
  • 3141
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALCASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 2014
ALCCHIA (Chi-X Australia)YesOrdinary SharesAUAUDAug 2014

Biography

Alcidion Group Limited engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision that combines artificial ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/08 10:33
End of Day Share Price2020/08/07 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.